Market capitalization | $42.06m |
Enterprise Value | $-104.51m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 1.32 |
EV/Sales (TTM) EV/Sales | -14.93 |
P/S ratio (TTM) P/S ratio | 6.01 |
P/B ratio (TTM) P/B ratio | 0.28 |
Revenue (TTM) Revenue | $7.00m |
EBIT (operating result TTM) EBIT | $-99.54m |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
6 Analysts have issued a Kezar Life Sciences Inc forecast:
6 Analysts have issued a Kezar Life Sciences Inc forecast:
Jun '24 | |
Current assets | 168 168 |
Fixed assets | 12 12 |
Total Assets | 180 180 |
Jun '24 | |
Equity | 151 151 |
Debt capital | 29 29 |
Total Capital | 180 180 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company, which engages in the development of novel small molecule therapeutics to treat autoimmunity and cancer in South San Francisco, California. Its product pipeline include KZR-616, KZR-261, and KZR-TBD. The company was founded by John Fowler, Christopher J. Kirk, and Jack Taunton on February 20, 2015 and is headquartered in South San Francisco, CA.
Head office | United States |
CEO | Christopher Kirk |
Employees | 58 |
Founded | 2015 |
Website | www.kezarlifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.